NOVN.CH

118.84

-1.25%↓

LONN.CH

534.6

+1.17%↑

SDZ.CH

67.86

+0.89%↑

STMN.CH

88.7

+1.39%↑

BANB.CH

72.6

-1.29%↓

NOVN.CH

118.84

-1.25%↓

LONN.CH

534.6

+1.17%↑

SDZ.CH

67.86

+0.89%↑

STMN.CH

88.7

+1.39%↑

BANB.CH

72.6

-1.29%↓

NOVN.CH

118.84

-1.25%↓

LONN.CH

534.6

+1.17%↑

SDZ.CH

67.86

+0.89%↑

STMN.CH

88.7

+1.39%↑

BANB.CH

72.6

-1.29%↓

NOVN.CH

118.84

-1.25%↓

LONN.CH

534.6

+1.17%↑

SDZ.CH

67.86

+0.89%↑

STMN.CH

88.7

+1.39%↑

BANB.CH

72.6

-1.29%↓

NOVN.CH

118.84

-1.25%↓

LONN.CH

534.6

+1.17%↑

SDZ.CH

67.86

+0.89%↑

STMN.CH

88.7

+1.39%↑

BANB.CH

72.6

-1.29%↓

Strona główna・Stock List・Roche Holding AG

Roche Holding AG

Open

SectorHealthcare

329.6 0.37

Buy Sell

Overview

Share price change

24h

Current

Min

328

Max

334.2

Key metrics
By Trading Economics
Income	1.8B 5.5B
Sales	15B 31B
P/E Sector Avg	20.586 66.418
Dividend yield	2.95
Profit margin	17.892
Employees	103,249
EBITDA	5.1B 12B

Dividends
By Dow Jones
Dividend yield Sector Avg	2.95% 2.36%

Market Stats
By TradingEconomics
Market Cap	-26B 263B
Previous open	329.23
Previous close	329.6

News Sentiment

By Acuity

17%

83%

32 / 348 Ranking in Healthcare

Roche Holding AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 mar 2026, 16:43 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mar 2026, 15:44 UTC

Major Market Movers

Correction to Roche Shares Article

9 mar 2026, 09:51 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mar 2026, 09:24 UTC

Major Market Movers

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 sty 2026, 10:07 UTC

Earnings

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 sty 2026, 07:07 UTC

Earnings

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

10 kwi 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 kwi 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 mar 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mar 2026, 09:43 UTC

Hot Stocks

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mar 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mar 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mar 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 sty 2026, 11:40 UTC

Market Talk

Earnings

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 sty 2026, 06:05 UTC

Earnings

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 sty 2026, 06:04 UTC

Earnings

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 sty 2026, 06:03 UTC

Earnings

Roche Issues 2026 View

29 sty 2026, 06:02 UTC

Earnings

Analysts Saw 2025 Core EPS at CHF19.70

29 sty 2026, 06:02 UTC

Earnings

Roche: 2025 Core EPS CHF19.46

29 sty 2026, 06:01 UTC

Earnings

Analysts Had Seen 2025 Sales At CHF61.47B

29 sty 2026, 06:01 UTC

Earnings

Roche 2025 Sales CHF61.52B

28 sty 2026, 11:22 UTC

Earnings

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 sty 2026, 11:31 UTC

Market Talk

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 sty 2026, 11:24 UTC

Market Talk

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 sty 2026, 09:30 UTC

Market Talk

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 sty 2026, 07:52 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Roche Obesity Study Data Look Encouraging -- Market Talk

16 sty 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 sty 2026, 14:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Pharma Sector Can Spend Big on M&A -- Market Talk

22 gru 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 lis 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

Peer Comparison

Price change

Roche Holding AG Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Roche Holding AG - Dist in the past 3 months.

Sentiment

By Acuity

32 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.